Improvement of intestinal absorption of azetirelin, a new TRH analogue, by absorption enhancers.
スポンサーリンク
概要
- 論文の詳細を見る
Azetireiin, a new thyrotropin-releasing hormone (TRH)analogue, has much more potent and longer-lasting activity on the central nervous system than TRH. It is known, however, that the oral bioavailability of azetirelin is poor and less than 2% in rats and humans. This is mainly attributed to the low intestinal permeability due to the lack of lipophilicity. We have studied the effect of various absorption enhancers on the intestinal absorption of azetirelin by means of <I>in vitro</I> Ussing chamber and <I>in situ</I> closed loop experiments. Enhancers such as Na<SUB>2</SUB>-EDTA, sodium glycocholatc(Na-GC), citric acid, and laurylmaltoside(LM) were used in the study. The action of these enhancers was more predominant in the large intestine than in the small intestine. LM was most effective among the enhancers studied. The enhancing activity of LM was concentration dependent and the effect of 1mM LM was still more extensive than that of 10mM of other enhancers. The release amount of membrane protein and phospholipid in the presence of these enhancers was also examined to evaluate the tissue damage. The results indicated that 1mM LM was less harmful to the large intestinal mucosa than 10mM Na<SUB>2</SUB>-EDTA or Na-GC. From these results, we conclude that LM is practically safe and effective absorption enhancer for improving the large intestinal absorption of azetirelin.
- 日本DDS学会の論文
日本DDS学会 | 論文
- 固形腫瘍における分子標的薬の現状と課題 : 腎がんの経験から
- 前立腺がんにおけるホルモン療法
- ホルモン製剤のDDSの基礎と臨床 : 特集によせて
- SN-38内包高分子ミセルNK012日米独立 phase I 試験
- 多機能性エンベロープ型ナノ構造体による人工遺伝子デリバリーシステムの創製 : 第7回日本DDS学会永井賞受賞によせて